The Pattern of Pharmacological Treatment in Subjects with Metabolic Syndrome: Findings from Isfahan Healthy Heart Program

Document Type : Original Article(s)

Authors

1 Researcher in Biochemistry, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Associate Professor. Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

4 Data mining Researcher, Isfahan Mathematics House, Isfahan, Iran.

5 Professor, Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Background: Pharmacological therapy is a critical step in the management of individuals with Metabolic Syndrome (MetS) when lifestyle modifications can not to achieve the therapeutic goals.However, it is well-documented that other than weight loss, there is no single best therapy, and the treatment should consist of treatment of individual components of the MetS. The objective of this study was to investigate treatment of individual components of the MetS among a population–based sample of individuals with the clustering of those components of the MetS.Methods: A cross-sectional population-based study, a randomly collected sample of men and women living in three counties in central Iran participating in the baseline survey of a community –based program in 2000-2001 were examined. A questionnaire was completed for all participants to collect data regarding their demographic characteristics, medical status and history of medication use. In this study we determined the association between clustering of MetS components and pharmacological treatment of cardiovascular risk factors.Finding: The most common pharmacologic agent received by individuals with MetS were beta blockers (72.8%) used for controlling high blood pressure, followed by lipid lowering agents (36%) without significant gender difference.Conclusion: Our results exhibited Beta blockers, statins, fibrates and glybenclamid are more prevalent drugs among subjects with metabolic syndrome. Further research is needed to better elucidate the compliance behavior of patients who have been diagnosed with MetS.    

Keywords

References

  1. AlSaraj F, McDermott JH, Cawood T, McAteer S, Ali M, Tormey W, et al. Prevalence of the metabolic syndrome in patients with diabetes mellitus. Ir J Med Sci 2009; 178(3): 309-13.
  2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356-9.
  3. GhariPour M, Baghei A, Boshtam M, Rabiei K. Prevalence of metabolic syndrome among the adults of central of areas of Iran (as part of "Isfahan Healthy Heart Study"). Journal of Birjand University of Medical Sciences 2006; 13(3): 56-63.
  4. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009; 32(6): 1092-7.
  5. Sarrafzadegan N, Kelishadi R, Baghaei A, Hussein SG, Malekafzali H, Mohammadifard N, et al. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol 2008; 131(1): 90-6.
  6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-52.
  7. Misra A, Chaudhary D, Vikram NK, Mittal V, Devi JR, Pandey RM, et al. Insulin resistance and clustering of atherogenic risk factors in women belonging to low socio-economic strata in urban slums of North India. Diabetes Res Clin Pract 2002; 56(1): 73-5.
  8. Pacholczyk M, Ferenc T, Kowalski J. [Metabolic syndrome. Part III: its prevention and therapeutic management]. Postepy Hig Med Dosw (Online) 2008; 62: 559-70.
  9. Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J Assoc Physicians India 2006; 54: 797-810.
  10. Grundy SM. Metabolic syndrome: therapeutic considerations. Handb Exp Pharmacol 2005; (170): 107-33.
  11. May SH. Enteral supplementation and lifestyle intervention. Implications in the treatment of wasting syndrome in patients with HIV disease. AIDS Patient Care 1995; 9(1): 18-9.
  12. Tavassoli AA, Gharipour M, Khosravi A, Kelishadi R, Siadat ZD, Bahonar A, et al. Gender differences in obesogenic behaviour, socioeconomic and metabolic factors in a population-based sample of Iranians: the IHHP study. J Health Popul Nutr 2010; 28(6): 602-9.
  13. Dastjerdi MS, Kazemi F, Najafian A, Mohammady M, Aminorroaya A, Amini M. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. Int J Obes (Lond) 2007; 31(4): 713-7.
  14. Sarraf-Zadegan N, Sadri G, Malek AH, Baghaei M, Mohammadi FN, Shahrokhi S, et al. Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiol 2003; 58(4): 309-20.
  15. Sarraf-Zadegan N, Baghaei A, Sadri Gh, Kelishadi R, Malekafzali H, Boshtam M, et al. Isfahan healthy heart program: Evaluation of comprehensive, community-based interventions for non-communicable disease prevention. Prevention and Control 2006; 2(2): 73-84.
  16. Ryo M, Funahashi T. [Global diagnosis definition of the metabolic syndrome and its management]. Nippon Rinsho 2006; 64(Suppl 9): 463-9.
  17. Bjornsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2008; 54(1): 7-18.
  18. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004; 24(2): e13-e18.
  19. Israili ZH, Lyoussi B, Hernandez-Hernandez R, Velasco M. Metabolic syndrome: treatment of hypertensive patients. Am J Ther 2007; 14(4): 386-402.
  20. Katzmarzyk PT. A summary of the symposium "Current strategies in the prevention and treatment of obesity". Appl Physiol Nutr Metab 2006; 31(6): 767-8.
  21. Kirkendoll K, Clark PC, Grossniklaus D, Igho-Pemu P, Mullis R, Dunbar SB. Metabolic syndrome in African Americans: views on making lifestyle changes. J Transcult Nurs 2010; 21(2): 104-13.
  22. Mizushima S. [New health assessment and life style modification advice program for metabolic syndrome in Japan]. Nippon Rinsho 2006; 64(Suppl 9): 729-33.
  23. Okajima T, Tanaka K, Tanabe M, Hirase N, Tsubouchi H. [Practical benefits of application of clinical path to the patients with metabolic syndrome]. Nippon Rinsho 2006; 64(Suppl 9): 717-22.
  24. Oshida Y, Sato Y. [Approach in clinical management of metabolic syndrome. 8. Methods and effects of exercise therapy]. Nippon Naika Gakkai Zasshi 2004; 93(4): 726-32.
  25. Khosravi Ar, Shirani Sh, Shahrokhi Sh, Mohammadifard N, Ansari R. Antihypertensive drugs used by hypertensive patients in the provincial cities of Isfahan, Najafabad and Arak. Arya Atherosclerosis Journal 2006; 1(4): 275-80.
Journal of Isfahan Medical School
Volume 29, Issue 138 - Serial Number 138
March and April 2011
Pages 562-570

Files

History

  • Receive Date: 23 May 2011
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics